Published • loading... • Updated
FDA Clears AstraZeneca Prostate Cancer Therapy for PTEN Patients
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Clears AstraZeneca Prostate Cancer Therapy for PTEN Patients
WILMINGTON, DE — AstraZeneca’s TRUQAP (capivasertib) has won U.S. approval for a subset of patients with advanced prostate cancer, providing the first biomarker-targeted treatment option for an aggressive form of the disease linked to PTEN deficiency. The U.S. Food and Drug Administration approved TRUQAP in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostat…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
